دورية أكاديمية

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
المؤلفون: Kim, M. K., Rhee, E.‐J., Han, K. A., Woo, A. C., Lee, M.‐K., Ku, B. J., Chung, C. H., Kim, K.‐A., Lee, H. W., Park, I. B., Park, J. Y., Chul Jang, H. C., Park, K. S., Jang, W. I., Cha, B. Y.
المساهمون: Handok Inc., Seoul, Republic of Korea
المصدر: Diabetes, Obesity and Metabolism ; volume 17, issue 3, page 309-312 ; ISSN 1462-8902 1463-1326
بيانات النشر: Wiley
سنة النشر: 2015
المجموعة: Wiley Online Library (Open Access Articles via Crossref)
الوصف: The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in K orean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin ( HbA1c ) 7.0–10.0%, on stable metformin ≥1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin ( n = 136) or placebo plus metformin ( n = 68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were −0.78 % and −1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in K orean patients with type 2 diabetes.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1111/dom.12424
DOI: 10.1111/dom.12424/fullpdf
الإتاحة: https://doi.org/10.1111/dom.12424Test
حقوق: http://creativecommons.org/licenses/by-nc-nd/4.0Test/
رقم الانضمام: edsbas.4AD03926
قاعدة البيانات: BASE